×
Exelixis Inventory 2010-2024 | EXEL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Exelixis inventory for the quarter ending June 30, 2024 was
$0.021B
, a
28.01% decline
year-over-year.
Exelixis inventory for 2023 was
$0.017B
, a
47.98% decline
from 2022.
Exelixis inventory for 2022 was
$0.033B
, a
21.12% increase
from 2021.
Exelixis inventory for 2021 was
$0.027B
, a
31.09% increase
from 2020.
View More
Exelixis Inventory 2010-2024 | EXEL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Exelixis inventory for 2023 was
$0.017B
, a
47.98% decline
from 2022.
Exelixis inventory for 2022 was
$0.033B
, a
21.12% increase
from 2021.
Exelixis inventory for 2021 was
$0.027B
, a
31.09% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$178.8B
Regeneron Pharmaceuticals (REGN)
$126.4B
Vertex Pharmaceuticals (VRTX)
$124.2B
Gilead Sciences (GILD)
$103.4B
Bristol Myers Squibb (BMY)
$100.3B
CSL (CSLLY)
$97.4B
GSK (GSK)
$88.2B
Alnylam Pharmaceuticals (ALNY)
$35.2B
Argenex SE (ARGX)
$31.2B
BioNTech SE (BNTX)
$29.7B
Biogen (BIIB)
$28.9B
Moderna (MRNA)
$27.7B
Illumina (ILMN)
$20.7B
BeiGene (BGNE)
$19.2B
Genmab (GMAB)
$17.5B
BioMarin Pharmaceutical (BMRN)
$13.4B
Vaxcyte (PCVX)
$13B
Incyte (INCY)
$12.8B
Insmed (INSM)
$12.6B
Exact Sciences (EXAS)
$12.6B
Sarepta Therapeutics (SRPT)
$12B
Bio-Techne Corp (TECH)
$11.9B
QIAGEN (QGEN)
$10.4B
Legend Biotech (LEGN)
$9.3B
Bio-Rad Laboratories (BIO.B)
$9.1B
Roivant Sciences (ROIV)
$8.9B
Ascendis Pharma (ASND)
$8.5B
Intra-Cellular Therapies (ITCI)
$7.9B
Halozyme Therapeutics (HALO)
$7.8B
Repligen (RGEN)
$7.6B